Merck, Moderna Melanoma Vaccine Study Succeeds
Share
Merck and Moderna announced positive results from a large late-stage trial of their personalized mRNA cancer vaccine, which significantly reduced the recurrence of melanoma, the deadliest form of skin cancer. Madison Muller reports on "Bloomberg Open Interest."